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Introduction
The liver is the primary site of hormone and glucose
metabolism, and the intercommunication between liver
and diabetes has long been recognized. The majority of
patients with cirrhosis have glucose intolerance (60%)
or overt diabetes mellitus (DM, 20%).1 Additionally,
diabetic patients have abnormal liver function tests,2
hepatomegaly,3 hepatic steatosis,4 and steatohepatitis.5
In 1994, Allison et al6 reported that, among 34
hepatitis C virus (HCV)-related cirrhotic patients
awaiting liver transplantation, 17 (50%) had diabetes
mellitus, as opposed to only 9% of other cirrhotic
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patients unrelated with no HCV. During the same
year, Özyilkan et al7 noted an increased prevalence of
HCV antibodies in patients with DM, especially in
type 2 DM patients. Several subsequent studies also
reported a link between DM and chronic HCV infection
in both clinical8–21 and community22,23 settings. Previous
studies indicated that chronic hepatitis C induced
insulin resistance,24,25 which may contribute to the
fibrotic progression and subsequent development of
type 2 DM.
In southern Taiwan, 2 studies have analyzed the
relationship of HCV infection and type 2 DM. Wang
et al22 reported that HCV infection was moderately
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associated with type 2 diabetes in A-lein Township,
Kaohsiung County, but such correlation was not
found in Yuan-chang Township, Yuin-lin County.26
Some previous studies also demonstrated a negative
linkage between these 2 disorders.27–29 To our best
knowledge, there has been no prevalence study of
chronic hepatitis B or C in type 2 DM patients in
northern Taiwan. The objectives of this study were to
estimate the seroprevalence rates of hepatitis B and C
in type 2 DM patients visiting our endocrinology
clinics, and to explore the risk factors for hepatitis in
patients with type 2 DM.
Methods
We recruited all type 2 DM patients who consecutively
attended 2 of 5 outpatient endocrinology clinics at
Far Eastern Memorial Hospital (FEMH) during the
period March 1, 2003, to July 31, 2003. After the
aim of the study was explained to the patients, those
who gave informed consent were asked to fill out a
data sheet on demographics, diabetic data, and the
potential risk factors for hepatitis. Body weight and
height were measured and used to calculate body
mass index (BMI). We also measured concentrations
of alanine aminotransferase (ALT), fasting plasma
glucose (FPG) (Hitachi 747 Autonomic Analyzer,
Nakawork, Tokyo, Japan), and glycosylated
hemoglobin (HbA1c) (Primus CLC 385, Kansas,
MO, USA). Serologic testing for hepatitis B surface
antigen (HBsAg) and hepatitis C antibody (anti-
HCV) were performed using a third-generation
microparticle enzyme immunoassay (Abbott Labs,
Chicago, IL, USA). A total of 1,108 diabetic patients
were contacted, and 820 agreed to participate in
the study.
To compare the seroprevalence rates of hepatitis B
and C between type 2 DM patients and patients
without DM, we selected a reference group comprised
of 905 subjects who came for medical check-ups at
the Department of Family Medicine, FEMH, between
January 2002 and September 2003. We excluded
those individuals with FPG levels greater than 126
mg/dL. The information of the control group was
retrieved from the medical check-up records at the
Family Medicine Department. There were no major
systemic diseases in the control group except for 15%
and 4.2% who reported past histories of hypertension
and hyperlipidemia, respectively. According to the
records from medical check-ups, none had the
combination of hypertension, dyslipidemia, and
obesity.
Data were descriptively expressed as mean ( SD or
number and percent. Comparisons between groups
were made using Student’s t test for continuous
variables and Chi-square test for categorical data. A
multivariate logistic regression model was used to
determine the independent effect of various factors that
were potentially associated with the risk of hepatitis.
These factors included sociodemographic variables
(age, sex, educational status, active smoking, and alcohol
consumption), clinico-laboratory measurements
(BMI, HbA1c, and ALT), and clinical characteristics
(duration of diabetes, treatment regimens, previous
experiences of jaundice, hospital admission, surgical
operation, blood transfusions, intravenous drug abuse,
tattooing, hemodialysis, and abortion [for females
only]). All tests were two-sided with an _-level of 0.05.
Data were analyzed using the statistical software SPSS
version 10.0 (Chicago, IL, USA).
Results
Comparisons between the diabetic patient group
and the control group are shown in Table 1. Mean age,
BMI, ALT, and FPG were significantly higher in the
diabetic patients. Alcohol consumption was comparable
between these 2 groups. There was no significant
difference in HBsAg seropositivity in the diabetic
patients (13.5%) and the control subjects (12.4%)
(p = 0.441). On the other hand, anti-HCV seropositivity
was detected in 56 (6.8%) diabetic patients and in
23 (2.6%) control subjects (p < 0.001). After adjustment
for age, sex, BMI, and ALT, the odds ratios (OR) of
seropositivity on HBsAg and anti-HCV in relation to
type 2 DM were 1.09 (95% confidence interval [CI]:
0.77–1.55) and 2.87 (95% CI: 1.51–5.46), respectively.
As the prevalence rate increased only for anti-HCV
seropositivity, we limited the analysis to searching for
correlates of anti-HCV seropositivity in the diabetic
patients.
Table 2 presents sociodemographic variables,
clinico-laboratory measurements, and clinical
characteristics in relation to the risk of anti-HCV
in type 2 DM patients. The distributions of all
sociodemographic variables and clinical characteristics
were similar between anti-HCV positive and anti-
HCV negative diabetic patients. Diabetic patients,
with or without anti-HCV seropositivity, were also
similar in most clinico-laboratory measurements except
ALT levels. Abnormal ALT (* 24 IU/L) was observed
in 61.8% of the anti-HCV-positive diabetic patients
compared to only 34.2% in anti-HCV-negative diabetic
patients. Compared to anti-HCV-negative diabetic
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patients, anti-HCV-positive diabetic patients had
significantly higher odds of having an ALT level of
24–40 (age-sex-BMI adjusted OR = 2.93, 95% CI:
1.53–5.58) or greater than 40 (age-sex-BMI adjusted
OR = 3.39, 95% CI: 1.69–6.79).
Discussion
In this study, the seropositive prevalence rates of
HBsAg and anti-HCV in type 2 DM patients were
estimated to be 13.54% and 6.83%, respectively. In
comparison, individuals in the DM group showed a
2.8 times higher rate of anti-HCV seropositivity. On
the other hand, there was no significant difference in
the prevalence rate of HBsAg seropositivity between
type 2 diabetic patients and the reference sample.
Many previous studies, conducted in various
nations, including Turkey,7,19 the United Kingdom,10
Spain,11 the United States,13 Italy,17 and Korea,18 also
reported a higher prevalence rate of hepatitis C in
diabetic patients. Interpretations of the findings
from these studies, however, should be made with
caution — various control groups were used in these
studies, and the increased prevalence rate noted in
certain studies could merely be an artifact of control
selection. For example, some of the above-mentioned
studies11,17,19 selected blood donors as a control group
for which the prevalence rate of hepatitis C is normally
much lower.30 Mason et al13 collected the control
group from those patients who were referred for
radionuclide thyroid scans from the same clinic. The
prevalence rate of antibodies to hepatitis C in thyroid
illness patients is likely to be different from that of the
general population.31 In our study, the control group
comprised people who came for a medical check-up
in the same hospital. Type 2 DM patients in our
hospital had increased risk of exposure to hepatitis C
when compared with control subjects, but the
seroprevalence rate of anti-HCV in our patients was
still lower than in other high-risk groups noted in
previous studies.32–37
One may argue that the reason why diabetic patients
have a higher chance of exposure to hepatitis C is
because of self-monitoring of blood glucose, insulin
injection, and frequent hospitalization. If needle
exposure increases the prevalence of HCV infection, it
might also increase the prevalence of HBV infection.
In our study, the prevalence rate of hepatitis B was
similar to that of the control group.
Table 1. Comparisons between diabetic patients and control subjects
Diabetic patients* Control subjects* p†
Age (yr)* 56.95 ( 11.33 53.65 ( 15.28 < 0.001
BMI* 26.08 ( 4.20 24.40 ( 3.85 < 0.001
FPG (mg/dL)* 155.29 ( 56.53 92.58 ( 12.85 < 0.001
ALT (IU/L)* 26.68 ( 26.85 22.89 ( 20.72 0.001
Sex (n)
Male 428 52.21% 503 55.69% 0.159
Female 392 47.79% 402 44.31%
HBsAg (n)
Negative 709 86.46% 791 87.61% 0.441
Positive 111 13.54% 112 12.39%
Anti-HCV (n)
Negative 764 93.17% 877 97.44% < 0.001
Positive 56 6.83% 23 2.56%
Alcohol consumption‡ (n)
No 592 73.91% 666 76.10% 0.317
Yes 208 26.11% 210 23.90%
Total 820 100.0 905 100.0
*Means ( SD; †estimated from Student’s t test or Chi-square test; ‡inconsistencies between total number of patients and patients summed were
because of missing information; ALT = alanine aminotransferase; BMI = body mass index; FPG = fasting plasma glucose; HBsAg = hepatitis B surface
antigen; HCV = hepatitis C virus.
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Table continued on page 150
Table 2. Sociodemographic variables, clinico-laboratory measurements, and clinical characteristics related to the risk of
anti-HCV in type 2 DM patients
Anti-HCV (–) Anti-HCV (+) Adjusted OR
P
n (%) n (%) (95% CI)*
Sociodemographic variables
Age (yr)
< 40 39 (5.1) 3 (5.4) 1.0
40–65 555 (72.6) 36 (64.3) 0.84 (0.25–2.86) 0.785
> 65 170 (22.3) 17 (30.4) 1.30 (0.36–4.66) 0.687
Sex
Male 399 (52.2) 29 (51.8) 1.0
Female 365 (47.8) 27 (48.2) 1.02 (0.59–1.75) 0.949
Educational status
Primary school or lower 406 (55.8) 37 (69.8) 1.0
Middle school or higher 322 (44.2) 16 (30.2) 0.54 (0.27–1.06) 0.141
Active smoking
No 510 (67.8) 35 (62.5) 1.0
Yes 242 (32.2) 21 (37.5) 1.26 (0.72–2.22) 0.460
Alcohol consumption
No 553 (74.2) 38 (69.1) 1.0
Yes 192 (25.8) 17 (30.9) 1.29 (0.71–2.34) 0.427
Clinico-laboratory measurements
BMI
< 25 318 (43.1) 27 (50.0) 1.0
25–30 319 (43.2) 22 (40.7) 0.81 (0.45–1.46) 0.485
> 30 101 (13.7) 5 (9.3) 0.58 (0.22–1.55) 0.281
HbA1c (%)
< 7 248 (32.9) 19 (35.2) 1.0
7–8 216 (28.6) 15 (27.8) 0.91 (0.45–1.83) 0.784
> 8 290 (38.5) 20 (37) 0.90 (0.47–1.73) 0.752
ALT (IU/L)
< 24 498 (65.8) 21 (38.2) 1.0
24–40 154 (20.3) 19 (34.5) 2.93 (1.53–5.58) < 0.001
> 40 105 (13.9) 15 (27.3) 3.39 (1.69–6.79) < 0.001
Clinical characteristics
Duration of diabetes
< 1 year 32 (4.5) 5 (9.1) 1.0
> 1 year 686 (95.5) 50 (90.9) 0.37 (0.14–1.03) 0.058
Treatment regimen
Diet control with/without OHA 594 (78.6) 41 (73.2) 1.0
Insulin therapy with/ without OHA 192 (25.8) 17 (30.9) 1.39 (0.74–2.58) 0.305
*Separate multivariate logistic regression models with adjustment for age, sex, and BMI were used to estimate OR for individual potential risk factors;
ALT = alanine aminotransferase; BMI = body mass index; CI = confidence interval; HbA1c = glycosylated hemoglobin; HCV = hepatitis C virus;
OHA = oral hypoglycemic agents; OR = odds ratio; NA = not available.
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Initially, it was thought that diabetes might be one
extrahepatic manifestation of hepatitis C.38 Indeed, a
recent study reported that the virus itself, or the host
inflammatory response to HCV infection, contributed
to the development of insulin resistance and subsequent
long-term risk of type 2 DM.24 Other animal studies
also indicated that the insulin resistance in HCV core
gene transgenic mice was chiefly due to hepatic insulin
resistance, induced by an elevated intrahepatic tumor
necrosis factor-_ through suppressing tyrosine
phosphorylation of insulin receptor substrate-1.25
Hepatic steatosis in chronic hepatitis C contributed to a
morphologic expression of a cytopathic effect of HCV,39
and it also influenced liver fibrosis progression40,41
and ensuing worsening of insulin resistance.
Our study observed that type 2 DM patients with
a high ALT level had increased seroprevalence of
HCV. However, 34–75% of type 2 DM patients are
associated with nonalcoholic steatohepatitis (NASH),42
which is characterized by elevated ALT levels, so the
relationship between HCV infection and high liver
function tests should be made with caution. Because
34.2% of our anti-HCV-negative DM subjects also
had abnormal ALT levels, we suggest that NASH may
have contributed to those abnormal liver function
tests.
Table continued from page 149
Table 2. Sociodemographic variables, clinico-laboratory measurements, and clinical characteristics related to the risk of
anti-HCV in type 2 DM patients
Anti-HCV (–) Anti-HCV (+) Adjusted OR
P
n (%) n (%) (95% CI)*
History of jaundice
No 733 (97.6) 54 (96.4) 1.0
Yes 18 (2.4) 2 (3.6) 1.36 (0.30–6.12) 0.685
History of hospital admission
No 200 (26.5) 15 (26.8) 1.0
Yes 554 (73.5) 41 (73.2) 0.96 (0.50–1.81) 0.887
History of surgical operation
No 328 (43.5) 21 (37.5) 1.0
Yes 426 (56.5) 35 (62.5) 1.31 (0.73–2.34) 0.359
History of blood transfusion
No 640 (85.0) 44 (78.6) 1.0
Yes 113 (15.0) 12 (21.4) 1.53 (0.78–3.00) 0.218
History of intravenous drug abuse
No 753 (100.0) 55 (100.0) NA
Yes 0 (0.0) 0 (0.0)
History of tattooing
No 658 (87.3) 46 (82.1) 1.0
Yes 96 (12.7) 10 (17.9) 1.69 (0.77–3.69) 0.189
History of hemodialysis
No 752 (99.9) 55 (98.2) 1.0
Yes 1 (0.1) 1 (1.8) 13.67 (0.84–221.45) 0.134
History of abortion (females only)
No 185 (52.4) 15 (53.6) 1.0
Yes 168 (47.6) 13 (46.4) 0.92 (0.41–2.08) 0.845
Total 764 (100.0) 56 (100.0)
*Separate multivariate logistic regression models with adjustment for age, sex, and BMI were used to estimate OR for individual potential risk factors;
ALT = alanine aminotransferase; BMI = body mass index; CI = confidence interval; HbA1c = glycosylated hemoglobin; HCV = hepatitis C virus;
OHA = oral hypoglycemic agents; OR = odds ratio; NA = not available.
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Limitations of our study include the following
factors. First, we used only microparticle enzyme
immunoassay tests to determine the presence of
HCV infection without supplemental recombinant
immunoblot assay or HCV RNA test, which might
have resulted in false-positive HCV results. However,
previous studies suggested a high positive predictive
value for the enzyme immunoassay test when used
alone in the liver clinic population.43,44 Second, we did
not perform liver biopsies in all of our HCV-infected
diabetic patients, so we do not know the exact
pathologic grade and staging of chronic hepatitis C.
The possible inaccurate ascertainment of HCV infection
might entail a certain degree of misclassification of
disease and, subsequently, introduce information bias
into the study results. Such misclassification is, however,
likely to be non-differential, which would normally
bias the study results toward the null.45
The cross-sectional design of our study precluded
drawing an etiopathologically causal inference between
type 2 DM and the risks of HCV. A prospective cohort
study is required to ascertain the chronologic sequence
of acquiring HCV infection and the development of
type 2 DM. Despite that, as type 2 DM is associated
with a 2.8 times increased rate of hepatitis C, we have
to keep in mind the possibility of HCV infection for
our type 2 DM patients.
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